Parexel International Corp. (PRXL) Stock Price Down 4.5%
Parexel International Corp. (NASDAQ:PRXL)’s share price was down 4.5% during mid-day trading on Wednesday . The stock traded as low as $67.36 and last traded at $67.91, with a volume of 663,326 shares changing hands. The stock had previously closed at $71.11.
Several equities analysts have issued reports on PRXL shares. KeyCorp reissued a “hold” rating on shares of Parexel International Corp. in a research note on Sunday, May 22nd. Evercore ISI raised Parexel International Corp. from a “hold” rating to a “buy” rating in a research note on Wednesday, June 1st. Jefferies Group reissued a “hold” rating and issued a $70.00 price target on shares of Parexel International Corp. in a research note on Thursday, June 9th. Credit Suisse Group AG started coverage on Parexel International Corp. in a research note on Monday, June 20th. They issued an “outperform” rating and a $75.00 price target on the stock. They noted that the move was a valuation call. Finally, Robert W. Baird reissued an “outperform” rating and issued a $73.00 price target on shares of Parexel International Corp. in a research note on Monday, June 27th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $71.75.
The company’s 50 day moving average price is $67.61 and its 200-day moving average price is $63.04. The company has a market capitalization of $3.60 billion and a price-to-earnings ratio of 23.54.
Parexel International Corp. (NASDAQ:PRXL) last released its quarterly earnings results on Wednesday, August 3rd. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.01. The company had revenue of $538.60 million for the quarter, compared to the consensus estimate of $532.41 million. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.79 earnings per share. On average, equities research analysts anticipate that Parexel International Corp. will post $3.92 earnings per share for the current fiscal year.
In other Parexel International Corp. news, SVP Joshua Schultz sold 2,500 shares of the business’s stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $68.64, for a total transaction of $171,600.00. Following the sale, the senior vice president now directly owns 5,168 shares in the company, valued at approximately $354,731.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director A Dana Callow, Jr. sold 3,000 shares of the business’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $60.04, for a total transaction of $180,120.00. Following the sale, the director now owns 34,072 shares in the company, valued at $2,045,682.88. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Parexel International Corp. stock. I.G. Investment Management LTD. increased its position in Parexel International Corp. (NASDAQ:PRXL) by 1.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,029 shares of the company’s stock after buying an additional 545 shares during the period. I.G. Investment Management LTD. owned about 0.06% of Parexel International Corp. worth $2,318,000 at the end of the most recent quarter.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.